Tower Research Capital (TRC)’s Quantum Biopharma Class B Subordinate Voting Shares QNTM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$414 Buy
+115
New +$383 ﹤0.01% 5582
2026
Q2
– Sell
-71
Closed -$343 – 5744
2026
Q1
$343 Buy
+71
New +$320 ﹤0.01% 4903
2025
Q3
– Sell
-544
Closed -$11K – 5716
2025
Q2
$11K Sell
544
-2,651
-83% -$32.7K ﹤0.01% 3925
2025
Q1
$24.6K Buy
+3,195
New +$18.4K ﹤0.01% 2777

Other funds holding QNTM

Tower Research Capital (TRC)'s QNTM Position: Q3 2026 in Review

Tower Research Capital (TRC) opened a new position in Quantum Biopharma Class B Subordinate Voting Shares (QNTM) in Q3 2026: 115 shares worth $414. The stake represents ﹤0.01% of the portfolio and ranks #5582 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in QNTM as recently as Q1 2026.

Tower Research Capital (TRC) first reported a position in QNTM in Q1 2025 and has held it in 4 quarters since. The position peaked at $24.6K in Q1 2025. 28 funds tracked by Wall St. Rank hold QNTM as of Q3 2026.

  • Tower Research Capital (TRC) held 115 shares of Quantum Biopharma Class B Subordinate Voting Shares worth $414 as of Q3 2026.
  • Quantum Biopharma Class B Subordinate Voting Shares was a new Tower Research Capital (TRC) position in Q3 2026.
  • Quantum Biopharma Class B Subordinate Voting Shares made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q3 2026, its #5582 holding.
  • Tower Research Capital (TRC) first reported a position in Quantum Biopharma Class B Subordinate Voting Shares in Q1 2025 and has held it in 4 quarters since.
  • Tower Research Capital (TRC)'s Quantum Biopharma Class B Subordinate Voting Shares position peaked at $24.6K in Q1 2025.
  • 28 funds tracked by Wall St. Rank held Quantum Biopharma Class B Subordinate Voting Shares as of Q3 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2026, filed 16 Nov 2026.